Interim PET/CT-adapted Use of PD-1 Inhibitor Combined With De-escalated Chemotherapy-AVD in Classic Hodgkin Lymphoma

NCT07720011 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

130

Enrollment

OTHER

Sponsor class

Conditions

Classical Hodgkin Lymphoma

Interventions

DRUG: ABVD chemotherapy
DRUG: Sintilimab and AVD

Sponsor

Peking University People's Hospital